Dataset Information

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.

ABSTRACT: Venous thromboembolism (VTE) is a significant contributor to morbidity and mortality. To advance our understanding of the biology contributing to VTE, we conducted a genome-wide association study (GWAS) of VTE and a transcriptome-wide association study (TWAS) based on imputed gene expression from whole blood and liver. We meta-analyzed GWAS data from 18 studies for 30 234 VTE cases and 172 122 controls and assessed the association between 12 923 718 genetic variants and VTE. We generated variant prediction scores of gene expression from whole blood and liver tissue and assessed them for association with VTE. Mendelian randomization analyses were conducted for traits genetically associated with novel VTE loci. We identified 34 independent genetic signals for VTE risk from GWAS meta-analysis, of which 14 are newly reported associations. This included 11 newly associated genetic loci (C1orf198, PLEK, OSMR-AS1, NUGGC/SCARA5, GRK5, MPHOSPH9, ARID4A, PLCG2, SMG6, EIF5A, and STX10) of which 6 replicated, and 3 new independent signals in 3 known genes. Further, TWAS identified 5 additional genetic loci with imputed gene expression levels differing between cases and controls in whole blood (SH2B3, SPSB1, RP11-747H7.3, RP4-737E23.2) and in liver (ERAP1). At some GWAS loci, we found suggestive evidence that the VTE association signal for novel and previously known regions colocalized with expression quantitative trait locus signals. Mendelian randomization analyses suggested that blood traits may contribute to the underlying risk of VTE. To conclude, we identified 16 novel susceptibility loci for VTE; for some loci, the association signals are likely mediated through gene expression of nearby genes.

SUBMITTER: Lindstrom S

PROVIDER: S-EPMC6871304 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.

Lindström Sara S Wang Lu L Smith Erin N EN Gordon William W van Hylckama Vlieg Astrid A de Andrade Mariza M Brody Jennifer A JA Pattee Jack W JW Haessler Jeffrey J Brumpton Ben M BM Chasman Daniel I DI Suchon Pierre P Chen Ming-Huei MH Turman Constance C Germain Marine M Wiggins Kerri L KL MacDonald James J Braekkan Sigrid K SK Armasu Sebastian M SM Pankratz Nathan N Jackson Rebecca D RD Nielsen Jonas B JB Giulianini Franco F Puurunen Marja K MK Ibrahim Manal M Heckbert Susan R SR Damrauer Scott M SM Natarajan Pradeep P Klarin Derek D de Vries Paul S PS Sabater-Lleal Maria M Huffman Jennifer E JE Bammler Theo K TK Frazer Kelly A KA McCauley Bryan M BM Taylor Kent K Pankow James S JS Reiner Alexander P AP Gabrielsen Maiken E ME Deleuze Jean-François JF O'Donnell Chris J CJ Kim Jihye J McKnight Barbara B Kraft Peter P Hansen John-Bjarne JB Rosendaal Frits R FR Heit John A JA Psaty Bruce M BM Tang Weihong W Kooperberg Charles C Hveem Kristian K Ridker Paul M PM Morange Pierre-Emmanuel PE Johnson Andrew D AD Kabrhel Christopher C Trégouët David-Alexandre DA Smith Nicholas L NL

Blood 20191101 19

Venous thromboembolism (VTE) is a significant contributor to morbidity and mortality. To advance our understanding of the biology contributing to VTE, we conducted a genome-wide association study (GWAS) of VTE and a transcriptome-wide association study (TWAS) based on imputed gene expression from whole blood and liver. We meta-analyzed GWAS data from 18 studies for 30 234 VTE cases and 172 122 controls and assessed the association between 12 923 718 genetic variants and VTE. We generated variant ...[more]

PMID: 31420334

Similar Datasets

Project description:ObjectiveVenous thromboembolism (VTE) is reported to occur in up to 33% of patients undergoing major vascular surgery. Despite this high incidence, patients inconsistently receive timely VTE chemoprophylaxis. The true incidence of VTE among patients receiving delayed VTE chemoprophylaxis is unknown. We sought to identify the association of VTE chemoprophylaxis timing on VTE risk, postoperative transfusion rates, and 30-day mortality and morbidity in patients undergoing major open vascular surgery.MethodsPatients undergoing major open vascular surgery (open abdominal aortic aneurysm [oAAA] repair, aortofemoral bypass, and lower extremity infrainguinal bypass [LEB]) were identified using the Michigan Surgical Quality Collaborative (MSQC) between July 2012 and June 2015. The VTE rate was compared between patients receiving early versus delayed VTE chemoprophylaxis. VTE chemoprophylaxis delay was defined as therapy initiation more than 24 hours after surgery. The risk-adjusted association of the chemoprophylaxis timing and VTE development was determined using multivariable logistic regression. Blood transfusion rates, 30-day mortality, and postoperative complications were compared across groups.ResultsA total of 2421 patients underwent major open vascular surgery, including 196 oAAA repair, 259 aortofemoral bypass, and 1966 LEB. The overall incidence of 30-day VTE was 1.40%, ranging from 1.12% for LEB to 3.57% for oAAA repair. Among patients receiving early VTE chemoprophylaxis, the rate of VTE was 0.78% versus 2.26% among those with a delay in VTE chemoprophylaxis (P = .002). When accounting for the preoperative risk of VTE, delayed chemoprophylaxis was associated with a significantly higher risk of VTE (odds ratio, 2.38; 95% confidence interval, 1.12-5.06; P = .024). The early VTE chemoprophylaxis group was associated with a significantly decreased risk of bleeding compared with those with a delay (14.31% vs 18.90%; P = .002). Overall 30-day mortality and postoperative complications were similar with the exception of an associated higher rate of infectious complications in the delayed VTE chemoprophylaxis group, including superficial surgical site infection (6.00% vs 4.06%; P = .028), pneumonia (3.25% vs 1.85%; P = .028), urinary tract infection (2.95% vs 1.57%; P = .020), and severe sepsis (3.05% vs 1.71%; P = .029).ConclusionsAlthough patients undergoing major open vascular surgery have a low risk of VTE at baseline, there is a significantly greater risk of developing VTE among patients who have a delay in the administration of VTE chemoprophylaxis. Postoperative transfusion rates were significantly lower among patients receiving early chemoprophylaxis. There were no differences in the 30-day mortality and postoperative complications, except for infectious complications. Given these findings, surgeons should consider early chemoprophylaxis in the postoperative setting after major open vascular surgery without contraindication.

Dataset Information

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.

Publications

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets